The Conversation
The Conversation is an independent not-for-profit digital news source featuring expert analysis from academics and professionals on ongoing or hot-button issues. According to its Who We Are page, the Conversation "arose out of deep-seated concerns for the fading quality of our public discourse – and recognition of the vital role that academic experts can play in the public arena."
Type of Content
Approved Story
1
Format
Region
News Item Format
Standard
Image Caption
Wojciech Stróżyk/Alamy Stock Photo
Community
Autocurated
0
The Oxford-AstraZeneca vaccine was a critical part of the COVID-19 pandemic response. However, on May 7 2024, the European Commission announced the vaccine is no longer authorised for use.
This EU announcement was preceded by an application from AstraZeneca on March 27 2024 to withdraw the EU marketing authorisation. This development has been covered in various media outlets as primarily related to the known “adverse events”, namely a very small risk of blood clots. However, other factors are far more likely to be driving this decision.
The first AstraZeneca vaccine dose, outside of clinical trials, was administered on January 4 2021. In that year, about 2.5 billion doses were administered, and an estimated 6.3 million lives saved.
It was a key product at the peak of the pandemic. This includes during the emergence of the delta variant in India, across the first half of 2021 where, amid significant global supply issues, the AstraZeneca vaccine was one of the few tools available during that humanitarian crisis.